BridgeBio's Attruby Shows Superior Performance Against Pfizer's Vyndamax in Key Heart Study

Imagine living with a rare, progressive heart condition that relentlessly weakens your most vital organ. For patients battling transthyretin cardiac amyloidosis, or ATTR-CM, this is a daily reality. It's a debilitating disease where abnormal protein deposits stiffen the heart, leading to serious complications. For years, one particular treatment, Pfizer’s Vyndamax, has been a cornerstone for many. But now, it seems a new contender from BridgeBio Pharma, Attruby, is not just entering the ring, but showing some truly impressive results in real-world settings – perhaps even outperforming the established champion.

This isn't just about a new drug; it's about potentially shifting the landscape for hundreds of thousands worldwide affected by ATTR-CM. You see, BridgeBio's acoramidis, marketed as Attruby, and Pfizer’s tafamidis, known as Vyndamax, both aim to stabilize the faulty transthyretin protein, slowing the disease's progression. The big news just announced, on September 23, 2026, stems from a compelling real-world study that pits these two medications head-to-head, and the findings, well, they're certainly turning heads in the medical community.

What's truly striking is that patients taking acoramidis saw a remarkable 34% fewer instances of what clinicians call 'clinical worsening events.' Think about that for a moment – a significant drop in serious heart-related issues that could lead to hospital visits or a decline in overall health. This composite endpoint even included diuretic intensification, which, for those in the know, is often an early and crucial red flag indicating that heart failure is, unfortunately, worsening. To have such a pronounced benefit observed in actual patient experiences, rather than just controlled trial settings, really underscores Attruby's potential.

The study itself wasn't a small-scale affair. Drawing from extensive U.S. claims data, it encompassed 170 patients receiving Attruby and a larger group of 448 individuals on Vyndamax. These patients were enrolled between December 2024 and April 2025, with their progress carefully tracked through July 2025 – an average follow-up period of about 4.6 months. It's worth remembering that Attruby itself only received its FDA approval for ATTR-CM in November 2024, so to see such strong comparative data emerging so quickly after its market introduction is, frankly, incredibly encouraging for BridgeBio and, more importantly, for patients.

These compelling results have already found a home, being published in the respected medical journal Cardiology and Therapy. And it doesn't stop there; BridgeBio has indicated that we can expect even more real-world data to be unveiled at various fall medical meetings. This continued flow of information will undoubtedly provide deeper insights into Attruby's long-term efficacy and safety. For patients and clinicians grappling with this challenging condition, these findings from BridgeBio are more than just numbers; they represent a significant stride forward and a tangible spark of hope in the fight against ATTR-CM.